Last week, we hosted an esteemed group of consultants in Nashville for our roundtable, GLP‑1s + AI: Powering the Next Era of Cardiometabolic Care. Over two days, thought leaders explored the rapidly evolving AI policy landscape with Ben Moscovitch and examined how AI is transforming cardiometabolic care with insights from Dr. Faraz Ahmad. We also shared Omada’s latest AI-powered innovations, along with real-world GLP‑1 outcomes—including muscle mass preservation and sustained weight management. Thank you to the consultants who joined us, our expert speakers and partners, and the Omada team who brought this program to life. We look forward to continuing the conversation and collaborating to shape the next era of cardiometabolic care.
Join Horizon Day 2026 for a LinkedIn Live reveal of how Omada is redefining cardiometabolic care as GLP-1s reshape the obesity treatment landscape. Don't miss Omada's Sean Duffy and Wei-Li Shao as they showcase Omada’s integrated approach, including a walk-through of GLP-1 prescribing and the guided medication care experience. They'll also reveal the strategy and vision shaping the future of Omada's care model. We’ll be taking audience Q&A in real time during the event, so join us—and join the conversation.
For employers, the real GLP‑1 budget question isn’t just “What do they cost?”—it’s “What do we get for our spend?” Omada acts as a GLP‑1 value maximizer. Our GLP‑1 Care Track includes nutrition guidance, human coaching, and behavior‑change support around medication to improve persistence, manage side effects, and support healthy discontinuation so results last. Our research has shown that members in Omada’s GLP‑1 program achieved greater weight loss and better weight maintenance on average than real world evidence. Not all access is created equal - learn more about how to maximize value from the investment in this piece by Wei-Li Shao: https://lnkd.in/dcsC6h7k
The American Heart Association (AHA) recently released a Presidential Advisory with a stark warning: Healthcare affordability in America has reached a crisis point. We're spending nearly $5T a year on healthcare, and the AHA projects that healthcare costs related to cardiovascular disease will quadruple by 2050. Senior Director of Clinical Affairs, Kevin Masci, Pharm D, explains why virtual chronic condition care between doctor visits is exactly the kind of strategic investment the AHA is calling for. We shouldn’t have to choose between affordability and quality care. The solution is already here. It's time to scale it.
Flexible benefit design solutions. One place for virtual GLP‑1 care. Together, they’re a win for employers. At a time when GLP-1 usage is surging, Omada’s new GLP-1 Flex Care gives employers a way to support healthy weight loss for their employees without taking on expense. For members who independently purchase GLP-1 medications through established cash-pay channels, Omada can provide wraparound lifestyle support that’s proven to deliver outcomes — all in one place. At one year, outcomes included: 💡 ~2x greater average weight loss for GLP-1 members than real-world evidence with standard care 💡 67% continued GLP-1 usage compared to 47-49% in real-world evidence 💡 63% maintained or continued to lose weight post GLP-1 discontinuation
Omada Health is now available through OptumRx's Weight Engage program, meaning employers can now purchase Omada through all three largest PBMs. GLP-1s have changed the weight management conversation, but medication alone isn't the answer. Our recent research reinforces why: members pairing GLP-1s with Omada lost more fat and preserved more muscle mass compared to GLP-1 patients not in Omada’s program. The behavior change wrapped around the medication is what helps improve health outcomes. Through their Weight Engage program, OptumRx clients can now offer members Omada's integrated cardiometabolic platform: GLP-1 medication care paired with behavior change program that includes personalized coaching, nutrition and exercise support, side effect management, and community support. Learn more: https://lnkd.in/dGgz-EE6
The relationship between GLP‑1s, body composition, and movement is more complicated than a simple “miracle drug” or “muscle loss” story. When you look closely at new data from Omada’s Insights Lab alongside emerging research, a different narrative comes into focus: with the right support, people on GLP‑1s are not just losing weight, they’re changing how they move, function, and feel in ways that traditional metrics often miss. In our latest edition of Proof Points, Physical Therapist Todd Norwood, PT, DPT, FACHE and Endocrinologist Rajiv R. unpack what 12 weeks of real-world data tells us about fat vs. muscle loss, why physical function matters as much as the scale, and how to design GLP-1 programs that optimize the quality of weight loss—not just the quantity. Read it here ↓
Are GLP-1s driving the right kind of weight loss? Our latest body composition study examines what type of weight patients actually lose on hashtag#GLP-1s *with* and *without* Omada’s strength-focused exercise support. Here’s what we found: Omada members lost nearly 2x more weight and body fat vs. controls while preserving muscle mass. They also reported greater gains in mental health, physical function, and confidence in their weight loss. In this 6-minute conversation, Director of Clinical Affairs Crystal Onwu, PharmD, RPh joins Endocrinologist Rajiv R. and Physical Therapist Todd Norwood, PT, DPT, FACHE to dig deeper into these outcomes. You’ll learn: - Why body composition matters for cardiometabolic risk - How exercise type impacts outcomes during rapid weight loss - The role of guided support in improving mental health Watch it here ↓
If your GLP‑1 strategy stops at “pounds lost,” you may be leaving value on the table. In a new study of people newly starting GLP‑1s for weight managements, individuals supported by Omada’s GLP‑1 Care Track lost, on average, more total weight and more body fat without giving up more muscle than those on GLP‑1s without Omada—translating into better strength, mobility, and metabolic resilience over time. They also felt better: Omada members reported greater improvements in emotional health, day‑to‑day functioning, and confidence in their ability to manage weight, all of which are linked to sustained engagement and long‑term outcomes. 👉 For employers and health plans, the data suggest that GLP‑1 investments are most effective when paired with virtual, strength‑focused support that helps members lose more of the right kind of weight and maintain results. Learn more: https://lnkd.in/dUUrZQq9
What is the best GLP-1 benefits strategy? A flexible one. The majority of employers consider managing GLP-1 coverage and cost important, but finding a financially sustainable path for access can be difficult. That’s why Omada is introducing GLP-1 Flex Care, a new offering that will support employers looking to increase access to GLP-1 medications for obesity. Members who independently purchase GLP-1 medications through established cash-pay channels can now receive Omada's proven virtual care, including personalized coaching and lifestyle support, throughout their GLP-1 journey. They’ll also benefit from clinical evaluation, prescribing, and ongoing medical guidance and oversight. Since members purchase the medications directly, employers can offer a structured GLP-1 option without taking on open‑ended medication spend. GLP-1 Flex Care will be available for employers later in 2026. Want to learn more? https://lnkd.in/e6Zq8fpM
